The tweet was deleted by the author.
But we saved everything 🙂.
Arrowhead Pharmaceuticals has achieved a significant milestone with the FDA approval of its new therapy designed to lower triglycerides for adults suffering from Familial Chylomicronemia Syndrome (FCS).
Dr. Jennifer Hellawell characterized this approval with a single word: 'Exhilaration.' For patients dealing with this rare disease, the newly approved treatment brings hope and the potential for better disease management.